Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
PARSIPPANY, N.J., March 13, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that its management team is scheduled to present at the Barclays Global Healthcare Conference at 10:15 a.m. ET on Thursday, March 16, 2017, in Miami.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco, (973) 451-4030 [email protected]
